SCHEMBL5333029

SCHEMBL5333029

Cc1cc(OC2CN(CC[C@H](N)CO)C2)ccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
HRH1 P35367 3/20 0.39
CCR3 P51677 3/20 0.39
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
HRH3 Q9Y5N1 2/20 0.37
MCL1 Q07820 1/20 0.36
CHRM3 P20309 1/20 0.36
SCN9A Q15858 2/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
ADRA1A P35348 1/20 0.35
ESR1 P03372 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5333037 1.00 KMT2A (0.41) KMT2AMEN1PKMSMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL5338587 0.99 KMT2A (0.40) KMT2AMEN1PKMSMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL5338595 0.99 KMT2A (0.40) KMT2AMEN1PKMSMN1; SMN2NPC1
SCHEMBL5335013 0.89 SLC6A2 (0.44) KMT2AMEN1HRH1CCR3KDM4E
SCHEMBL5335008 0.89 SLC6A2 (0.44) KMT2AMEN1HRH1CCR3KDM4E
Hydrochloric Acid SCHEMBL5339660 0.88 SLC6A2 (0.43) KMT2AMEN1HRH1CCR3KDM4E
Hydrochloric Acid SCHEMBL5339666 0.88 SLC6A2 (0.43) KMT2AMEN1HRH1CCR3KDM4E
Hydrochloric Acid SCHEMBL5337850 0.85 FPR2 (0.39) HRH1CCR3HRH3CHRM3SCN9A
Hydrochloric Acid SCHEMBL5337841 0.85 FPR2 (0.39) HRH1CCR3HRH3CHRM3SCN9A
SCHEMBL5331649 0.82 SIGMAR1 (0.38) HRH1CCR3HTR1AHTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288537-B2 Azetidine derivatives as CCR-3 receptor antagonists NOVARTIS AG (CH) 2007-10-30 US disclosed
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists NOVARTIS AG (CH) 2005-10-06 US disclosed
EP-1487435-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2004-12-22 EP disclosed
WO-2003077907-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists CCR3, CCR1, CCR9 KMT2A 3058/4885MEN1 2078/4885PKM 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.